Randomized trial · people

SS-31: wearable data grouped responders with 100% accuracy

Checked against the paper Randomized trialPublished by PepVault

The takeaway

For elamipretide in Barth syndrome, this early work suggests wearable readings could one day help spot who responds, but it does not measure the drug's benefit itself.

Kind
Randomized trial
Studied in
People
Number studied
12
Published
2023
Journal
Orphanet J Rare Dis

What they tested

Could data from a wearable device tell apart people with Barth syndrome who did better or worse on elamipretide (SS-31), and predict how well they function?

How the study was done

A further analysis of a randomized, double-blind, placebo-controlled crossover trial (each person got both elamipretide and placebo, a dummy treatment, at different times) in 12 patients with Barth syndrome, a rare inherited disease that affects the heart and muscles. The team fed wearable readings of heart rate, breathing rate, activity and posture into a clustering model, a computer method that sorts people into groups by how alike their data look.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Patients were split at the middle value of each functional test into higher and lower scorers, and into best and worst responders to elamipretide. Sorting by functional level matched the real groups 60-93% of the time, with the best results for the 6-minute walk test (93%), the PROMIS fatigue score (87%) and the SWAY balance score (80%). Sorting by response to elamipretide matched the real groups in every case (100%).

What it doesn’t show

This was a small proof-of-concept study in 12 patients. It tested whether wearable data can sort patients into groups, not how much elamipretide helped, and responders were defined only as the better half of the group on each test.

The paper

Van den Eynde et al. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data. Orphanet J Rare Dis. 2023.

The compound

More studies on SS-31

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo